F.D.A. Approves New Weight-Loss Pill
nytimes.com
F.D.A. Approves New Weight-Loss Pill
In March, the F.D.A. approved Wegovy to reduce the risk of heart attack, stroke and cardiovascular-related death in adults who have heart disease and are overweight or have obesity.
How Does Ozempic Work? (Published 2024)
Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it seems less effective than injectable drugs
Daily pill could offer alternative to weight-loss injections
The appetite for weight-loss drugs, known as glp-1 agonists, has been insatiable since they hit the market a decade ago. In 2024 global spending on them reached $54bn, a figure that is sure to rise in the coming years. These drugs, better known under their brand names of Wegovy, Ozempic, Mounjaro and Zepbound, do not merely promise trimmer
... See moreet’s be clear: For those who need them — medically rather than cosmetically — the drugs are a godsend. The primary indication for Ozempic and Mounjaro — and the only condition they are currently FDA-approved for — is the treatment of type-2 diabetes (the lifestyle-contingent, typically adult-onset diabetes, as opposed to the rarer type-1 diabetes,... See more
Article
Weight loss and disordered eating communities have long had a presence on social media platforms like X (formerly Twitter), Tumblr, YouTube, WeHeartIt, and Instagram. But in the past few years, weight loss content on TikTok was intensified by the development and popularity of GLP-1 medications like Ozempic, Mounjaro, and Wegovy. Many experts and... See more